COMPANY

Xemed

HQ: Durham, NH source · xemed.com ↗ · New England

Location: Durham, NH · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: COPD Non-Small-Cell Lung Carcinoma Asthma Bronchopulmonary Dysplasia Lung Transplant Rejection cystic fibrosis

8Trials (company is sponsor)38NIH grants

Timeline

Mar 1, 2027 Trial start Phase 1/Phase 2: Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI source ↗
Aug 1, 2026 Trial start Phase 1: 129Xe MRI in Pediatric Population With BPD source ↗
Sep 1, 2025 Trial start —: Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation source ↗
Feb 14, 2025 Grant Government grant — NIH R01: $708,917 (annual award, as published), announced Feb 14, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Oct 20, 2023 Trial start Phase 1: Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI source ↗
Mar 17, 2023 Trial start Phase 1: Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI source ↗
Jan 19, 2021 Trial start —: Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI source ↗
2013-03 Trial start Phase 2/Phase 3: Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI source ↗
2011-09 Trial start Phase 2: MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects source ↗

Upcoming milestones

Feb 29, 2028 (ESTIMATED) · Phase 1/Phase 2 · Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI · NCT07355231

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Feb 14, 2025 Government grant — NIH R01: $708,917 (annual award, as published), announced Feb 14, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT07355231	Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI	Phase 1/Phase 2	Not yet recruiting	Mar 1, 2027	Feb 29, 2028 (estimated)
NCT04035629	129Xe MRI in Pediatric Population With BPD	Phase 1	Withdrawn	Aug 1, 2026	Jul 31, 2031 (estimated)
NCT05816616	Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation	Not listed	Withdrawn	Sep 1, 2025	Apr 30, 2030 (estimated)
NCT05302817	Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI	Phase 1	Terminated	Mar 17, 2023	Feb 28, 2025 (actual)
NCT04941573	Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI	Not listed	Terminated	Jan 19, 2021	Sep 4, 2025 (actual)
NCT05433961	Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI	Phase 1	Terminated	Oct 20, 2023	Sep 11, 2025 (actual)
NCT01832363	Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI	Phase 2/Phase 3	Completed	2013-03	2018-12 (actual)
NCT01833390	MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects	Phase 2	Completed	2011-09	2015-01 (actual)

NIH awards 38

Annual award amounts. Total $14.7M.

Feb 19, 2024 NIH award 5R01CA255434-03 FY2024: $674,175 awarded for that fiscal year; activity R01 (OTHER_NIH); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Lung Functional Avoidance Radiotherapy Usi source ↗
Aug 31, 2022 NIH award 5R01CA255434-02 FY2022: $696,450 awarded for that fiscal year; activity R01 (OTHER_NIH); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Lung Functional Avoidance Radiotherapy Usi source ↗
Sep 17, 2021 NIH award 1R01CA255434-01A1 FY2021: $662,399 awarded for that fiscal year; activity R01 (OTHER_NIH); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Lung Functional Avoidance Radiotherapy U source ↗
Dec 2, 2016 NIH award 5R44HL117337-04 FY2017: $499,977 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Assessment of lung function in neonates and inf source ↗
Aug 21, 2015 NIH award 5R44HL112397-04 FY2015: $362,900 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Single-session bronchial thermoplasty for sever source ↗
Jul 14, 2015 NIH award 2R44HL117337-03 FY2015: $499,974 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Assessment of lung function in neonates and inf source ↗
Aug 11, 2014 NIH award 5R44HL112397-03 FY2014: $590,676 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Single-session bronchial thermoplasty for sever source ↗
Aug 21, 2013 NIH award 4R44HL112397-02 FY2013: $617,019 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Single-session bronchial thermoplasty for sever source ↗
Aug 15, 2013 NIH award 5R44HL087550-06 FY2013: $949,497 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Regulatory Advancement of HXe as a Diagnostic M source ↗
Aug 7, 2013 NIH award 5R43HL117337-02 FY2013: $241,662 awarded for that fiscal year; activity R43 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Assessment of lung function in neonates and inf source ↗
Sep 4, 2012 NIH award 1R43HL108452-01A1 FY2012: $219,649 awarded for that fiscal year; activity R43 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Xenon MRI assessment of response to cystic fi source ↗
Aug 16, 2012 NIH award 1R44HL112397-01 FY2012: $277,820 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Single-session bronchial thermoplasty for sever source ↗
Aug 15, 2012 NIH award 1R43HL117337-01 FY2012: $244,667 awarded for that fiscal year; activity R43 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Assessment of lung function in neonates and inf source ↗
Aug 15, 2012 NIH award 5R44HL087550-05 FY2012: $974,748 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Regulatory Advancement of HXe as a Diagnostic M source ↗
Aug 20, 2011 NIH award 2R44HL087550-04A1 FY2011: $999,987 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Regulatory Advancement of HXe as a Diagnostic source ↗
Jun 28, 2011 NIH award 5R44HL083545-03 FY2011: $374,931 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Optimized whole-lung mapping of the oxygen conc source ↗
Jul 9, 2010 NIH award 2R44HL083545-02 FY2010: $374,983 awarded for that fiscal year; activity R44 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Optimized whole-lung mapping of the oxygen conc source ↗
Aug 27, 2009 NIH award 5R44HL087550-03 FY2009: $380,947 awarded for that fiscal year; activity R44 (SBIR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Scale Up of Hyperpolarized Xe Production source ↗
Aug 7, 2009 NIH award 5R42HL082013-03 FY2009: $371,091 awarded for that fiscal year; activity R42 (STTR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Hyperpolarized xenon functional MRI of human lu source ↗
Jun 12, 2009 NIH award 5R44EB007439-03 FY2009: $294,971 awarded for that fiscal year; activity R44 (SBIR); PI WATT, DAVID; recipient as written: XEMED, LLC, DURHAM, NH. Production, validation, and commercialization of MagniLium ( source ↗
Sep 22, 2008 NIH award 1R43HL083545-01A1 FY2008: $99,355 awarded for that fiscal year; activity R43 (SBIR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Hyperpolarized xenon MRI of oxygen in human lu source ↗
Aug 30, 2008 NIH award 2R44HL087550-02A1 FY2008: $391,198 awarded for that fiscal year; activity R44 (SBIR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Scale Up of Hyperpolarized Xe Production source ↗
Aug 18, 2008 NIH award 2R42HL082013-02A2 FY2008: $380,764 awarded for that fiscal year; activity R42 (STTR); PI RUSET, IULIAN CONSTANTIN; recipient as written: XEMED, LLC, DURHAM, NH. Hyperpolarized xenon functional MRI of human source ↗
Jul 12, 2008 NIH award 1R41HL091578-01 FY2008: $99,999 awarded for that fiscal year; activity R41 (STTR); PI RUPPERT, KAI; recipient as written: XEMED, LLC, DURHAM, NH. Compartment-selective XTC MRI in Humans source ↗
Jun 10, 2008 NIH award 2R44EB007439-02 FY2008: $454,818 awarded for that fiscal year; activity R44 (SBIR); PI WATT, DAVID; recipient as written: XEMED, LLC, DURHAM, NH. Production, validation, and commercialization of MagniLium ( source ↗
Dec 6, 2007 NIH award 5R42ES014005-03 FY2008: $467,415 awarded for that fiscal year; activity R42 (STTR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Polarized Xenon Production: Powerful Narrowed Laser source ↗
Sep 24, 2007 NIH award 1R41CA128895-01 FY2007: $152,470 awarded for that fiscal year; activity R41 (STTR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Lung parenchyma loss in smokers measured with HyXeMRI source ↗
May 11, 2007 NIH award 2R42ES014005-02 FY2007: $282,207 awarded for that fiscal year; activity R42 (STTR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Polarized Xenon Production: Powerful Narrowed Laser source ↗
May 10, 2007 NIH award 1R43EB007439-01 FY2007: $172,520 awarded for that fiscal year; activity R43 (SBIR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Production, validation, and commercialization of Magn source ↗
Mar 19, 2007 NIH award 1R43HL087550-01 FY2007: $104,747 awarded for that fiscal year; activity R43 (SBIR); PI DISTELBRINK, JAN H; recipient as written: XEMED, LLC, DURHAM, NH. Scale Up of Hyperpolarized Xe Production source ↗